Skip to content

Octagon Capital Advisors LP

Follow

13F filer, CIK 1839435, NEW YORK, NY

Octagon Capital Advisors LP reported $750,613,938 across 26 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 83.66% of the portfolio.

Accepted , ingested 13F-HR 0001839435-26-000006

Period
2026-09-30
Reported value
$751M
Holdings
26
Top 10 weight
83.66%
New
2
Sold out
3

Part of the filer group Octagon Capital Advisors LP

  • Octagon Investments Master Fund LP
  • Ting Jia
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
OBXnew+2,414,610$33.2M
TNGXnew+630,000$15.7M
AVBPadded+170,333$5.16M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
GOSSreduced-7,653,125-$90.7M
ALMSexited-2,830,700-$79.7M
SMMTexited-1,250,000-$18.2M
DFTXreduced-439,000-$16.7M
MIRMreduced-169,450-$14.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001839435-26-000006, largest first. % of portfolio is the value over $740,058,738, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,110,167 shares; 2025Q1: 2,341,667 shares; 2025Q2: 2,341,667 shares; 2025Q3: 2,416,667 shares; 2025Q4: 2,416,667 shares; 2026Q1: 1,946,667 shares; 2026Q2: 1,841,667 shares; 2026Q3: 1,686,667 shares 1,686,667$149M20.07%-155,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 1,230,000 shares; 2025Q2: 1,267,000 shares; 2025Q3: 1,325,000 shares; 2025Q4: 756,000 shares; 2026Q1: 677,000 shares; 2026Q2: 993,000 shares; 2026Q3: 993,000 shares 993,000$98.3M13.29%0Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,440,000 shares; 2026Q2: 2,950,000 shares; 2026Q3: 2,511,000 shares 2,511,000$95.6M12.91%-439,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,763,000 shares; 2025Q1: 2,763,000 shares; 2025Q2: 2,763,000 shares; 2025Q3: 2,874,111 shares; 2025Q4: 2,350,000 shares; 2026Q1: 2,350,000 shares; 2026Q2: 2,350,000 shares; 2026Q3: 2,350,000 shares 2,350,000$75.2M10.17%0Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,059,387 shares; 2025Q1: 2,059,387 shares; 2025Q2: 1,946,054 shares; 2025Q3: 1,971,054 shares; 2025Q4: 1,971,054 shares; 2026Q1: 1,971,054 shares; 2026Q2: 1,971,054 shares; 2026Q3: 2,141,387 shares 2,141,387$64.8M8.76%+170,333Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 10,450,000 shares; 2025Q1: 10,700,000 shares; 2025Q2: 12,592,500 shares; 2025Q3: 9,067,500 shares; 2025Q4: 8,859,911 shares; 2026Q1: 8,859,911 shares; 2026Q2: 9,693,244 shares; 2026Q3: 9,693,244 shares 9,693,244$47.2M6.38%0Timeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,414,610 shares 2,414,610$33.2M4.48%newTimeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 266,000 shares; 2025Q3: 360,000 shares; 2025Q4: 535,000 shares; 2026Q1: 425,000 shares; 2026Q2: 310,000 shares; 2026Q3: 205,000 shares 205,000$22.9M3.1%-105,000Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 270,000 shares; 2026Q2: 270,000 shares; 2026Q3: 270,000 shares 270,000$17.7M2.39%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 630,000 shares 630,000$15.7M2.12%newTimeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 490,000 shares; 2026Q2: 490,000 shares; 2026Q3: 420,000 shares 420,000$15.6M2.11%-70,000Timeline
ANLADLAI NORTYE GROUP LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 934,716 shares; 2026Q3: 934,716 shares 934,716$15M2.02%0Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 338,900 shares; 2026Q2: 338,900 shares; 2026Q3: 169,450 shares 169,450$14.5M1.96%-169,450Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 960,847 shares; 2026Q2: 960,847 shares; 2026Q3: 713,000 shares 713,000$13.9M1.88%-247,847Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 9,567,898 shares; 2026Q1: 10,276,317 shares; 2026Q2: 10,276,317 shares; 2026Q3: 10,276,317 shares 10,276,317$13.9M1.87%0Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,598,000 shares; 2026Q1: 1,748,000 shares; 2026Q2: 1,748,000 shares; 2026Q3: 1,300,000 shares 1,300,000$9.22M1.25%-448,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 778,000 shares; 2025Q1: 769,815 shares; 2025Q2: 672,595 shares; 2025Q3: 722,595 shares; 2025Q4: 671,465 shares; 2026Q1: 165,000 shares; 2026Q2: 456,721 shares; 2026Q3: 249,000 shares 249,000$7.9M1.07%-207,721Timeline
GYREGYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 954,416 shares; 2026Q3: 954,416 shares 954,416$7M0.95%0Timeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,018,021 shares; 2025Q3: 1,018,021 shares; 2025Q4: 574,200 shares; 2026Q1: 574,200 shares; 2026Q2: 574,200 shares; 2026Q3: 574,200 shares 574,200$6.75M0.91%0Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,425,000 shares; 2025Q1: 2,425,000 shares; 2025Q2: 2,425,000 shares; 2025Q3: 2,624,000 shares; 2025Q4: 2,623,600 shares; 2026Q1: 3,166,600 shares; 2026Q2: 2,075,000 shares; 2026Q3: 599,900 shares 599,900$4.6M0.62%-1,475,100Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 3,322,000 shares; 2025Q2: 3,672,000 shares; 2025Q3: 2,815,000 shares; 2025Q4: 2,815,000 shares; 2026Q1: 1,485,000 shares; 2026Q2: 315,000 shares; 2026Q3: 315,000 shares 315,000$4.51M0.61%0Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 361,010 shares; 2026Q3: 100,000 shares 100,000$2.97M0.4%-261,010Timeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,917,995 shares; 2026Q1: 2,236,732 shares; 2026Q2: 1,350,000 shares; 2026Q3: 430,000 shares 430,000$2.69M0.36%-920,000Timeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,000,000 shares; 2026Q3: 275,000 shares 275,000$1.29M0.17%-725,000Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 18,350,000 shares; 2025Q1: 18,350,000 shares; 2025Q2: 18,350,000 shares; 2025Q3: 17,050,000 shares; 2025Q4: 13,915,371 shares; 2026Q1: 7,750,000 shares; 2026Q2: 7,750,000 shares; 2026Q3: 96,875 shares 96,875$1.15M0.16%-7,653,125Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ERASCA INCERASCA INC CALLcall720,000$10.6M-535,000

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ALMSALUMIS INC2,830,700$79.7Mshares
SMMTSUMMIT THERAPEUTICS INC1,250,000$18.2Mshares
CNTXCONTEXT THERAPEUTICS INC3,050,000$1.69Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001839435-26-000006 base2026-11-16